Targeting of leukemia-initiating cells to develop curative drug therapies: Straightforward but nontrivial concept

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 56-71

  Valent, P ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Drug resistance; Leukemia; Leukemic stem cells; Targeted drugs

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 CHLORO N [4 CHLORO 3 (2 PYRIDINYL)PHENYL] 4 METHANESULFONYLBENZAMIDE; ANTINEOPLASTIC AGENT; BGT 226; BOSUTINIB; CALICHEAMICIN; CD33 ANTIGEN; DASATINIB; EVEROLIMUS; GEMTUZUMAB; HYBRID PROTEIN; IMATINIB; KRN 383; LESTAURTINIB; MIDOSTAURIN; MK 0752; MONOCLONAL ANTIBODY; NILOTINIB; OBATOCLAX; OZOGAMICIN; PICEATANNOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; R 4733; RAPAMYCIN; RX 0201; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VEL 015; XL 147;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; GENE EXPRESSION; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; SYSTEMIC MASTOCYTOSIS;

ANIMALS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS;

EID: 78951476130     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743655     Document Type: Article

References (159)

1. Daub, H.; Specht, K.; Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 2004, 3, 1001-1010.
2. McLornan, D. P.; McMullin, M. F.; Johnston, P.; Longley, D. B. Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin. Drug Metab. Toxicol. 2007, 3, 363-377.
3. Raguz, S.; Yagüe, E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br. J. Cancer 2008, 99, 387-391.
4. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
5. Blair, A.; Hogge, D. E.; Sutherland, H. J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR-. Blood 1998, 92, 4325-4335.
6. Holyoake, T. L.; Jiang, X.; Jorgensen, H. G.; Graham, S.; Alcorn, M. J.; Laird, C.; Eaves, A. C.; Eaves, C. J. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001, 97, 720-728.
7. Hope, K. J.; Jin, L.; Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity. Nat. Immunol. 2004, 5, 738-743.
8. Bruns, I.; Czibere, A.; Fischer, J. C.; Roels, F.; Cadeddu, R. P.; Buest, S.; Bruennert, D.; Huenerlituerkoglu, A. N.; Stoecklein, N. H.; Singh, R.; Zerbini, L. F.; Jäger, M.; Kobbe, G.; Gattermann, N.; Kronenwett, R.; Brors, B.; Haas, R. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009, 23, 892-899.
9. Passegué, E.; Weisman, I. L. Leukemic stem cells: where do they come from? Stem Cell Rev. 2005, 1, 181-188.
10. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J.L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351, 657-667.
11. Michor, F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells 2007, 25, 1114-1118.
12. Minami, Y.; Stuart, S. A.; Ikawa, T.; Jiang, Y.; Banno, A.; Hunton, I. C.; Young, D. J.; Naoe, T.; Murre, C.; Jamieson, C. H.; Wang, J. Y. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc. Natl. Acad. Sci. (USA) 2008, 105, 17967-17972.
13. Barnes, D. J.; Melo, J. V. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5, 2862-2866.
14. Elrick, L. J.; Jorgensen, H. G.; Mountford, J. C.; Holyoake, T. L. Punish the parent not the progeny. Blood 2005, 105, 1862-1866.
15. Kavalerchik, E.; Goff, D.; Jamieson, C. H. Chronic myeloid leukemia stem cells. J. Clin. Oncol. 2008, 26, 2911-2915.
16. Valent, P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br. J. Haematol. 2008, 142, 361-378.
17. Jabbour, E.; Cortes, J. E.; Kantarjian, H. M. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer 2008, 112, 2112-2128.
18. Freeman, S. D.; Jovanovic, J. V.; Grimwade, D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin. Oncol. 2008, 35, 388-400.
19. Kern, W.; Haferlach, C.; Haferlach, T.; Schnittger, S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008, 112, 4-16.
20. Colmone, A.; Amorim, M.; Pontier, A. L.; Wang, S.; Jablonski, E.; Sipkins, D. A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322, 1861-1865.
21. Lane, S. W.; Scadden, D. T.; Gilliland, D. G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114, 1150-1157.
22. Han, L.; Wierenga, A.T.; Rozenveld-Geugien, M.; van de Lande, K.; Vellenga, E.; Schuringa, J. J. Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One 2009, 4, e7989.
23. Hu, Y.; Chen, Y.; Douglas, L.; Li, S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23, 109-116.
24. Dierks, C.; Beigi, R.; Guo, G. R.; Zirlik, K.; Stegert, M. R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14, 238-249.
25. Devireddy, L. R.; Gazin, C.; Zhu, X.; Green, M. R. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 2005, 123, 1293-1305.
26. Arlinghaus, R.; Leng, X. Requirement of lipocalin 2 for chronic myeloid leukemia. Leuk. Lymphoma 2008, 49, 600-603.
27. Taussig, D.C.; Miraki-Moud, F.; Anjos-Afonso, F.; Pearce, D. J.; Allen, K.; Ridler, C.; Lillington, D.; Oakervee, H.; Cavenagh, J.; Agrawal, S. G.; Lister, T.A.; Gribben, J. G.; Bonnet, D. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112, 568-575.
28. Wulf, G. G.; Wang, R. Y.; Kuehnle, I.; Weidner, D.; Marini, F.; Brenner, M. K.; Andreeff, M.; Goodell, M. A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001, 98, 1166-1173.
29. Moshaver, B.; van Rhenen, A.; Kelder, A.; van der Pol, M.; Terwijn, M.; Bachas, C.; Westra, A. H.; Ossenkoppele, G. J.; Zweegman, S.; Schuurhuis, G. J. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008, 26, 3059-3067.
30. Cheung, A. M.; Wan, T. S.; Leung, J. C.; Chan, L. Y.; Huang, H.; Kwong, Y. L.; Liang, R.; Leung, A. Y. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21, 1423-1430.
31. Pearce, D. J.; Taussig, D.; Simpson, C.; Allen, K.; Rohatiner, A. Z.; Lister, T. A.; Bonnet, D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23, 752-760.
32. Blair, A.; Sutherland, H. J. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp. Hematol. 2000, 28, 660-671.
33. Vercauteren, S.M.; Sutherland, H. J. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001, 3, 449-459.
34. Florian, S.; Sonneck, K.; Hauswirth, A. W.; Krauth, M. T.; Schernthaner, G. H.; Sperr, W. R.; Valent, P. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk. Lymphoma 2006, 47, 207-222.
35. van Rhenen, A.; van Dongen, G.A.; Kelder, A.; Rombouts, E. J.; Feller, N.; Moshaver, B.; Stigter-van Walsum, M.; Zweegman, S.; Ossenkoppele, G. J.; Jan Schuurhuis, G. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007, 110, 2659-2666.
36. Hosen, N.; Park, C. Y.; Tatsumi, N.; Oji, Y.; Sugiyama, H.; Gramatzki, M.; Krensky, A. M.; Weissman, I. L. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. (USA) 2007, 104, 11008-11013.
37. Jordan, C.T.; Upchurch, D.; Szilvassy, S. J.; Guzman, M. L.; Howard, D. S.; Pettigrew, A. L.; Meyerrose, T.; Rossi, R.; Grimes, B.; Rizzieri, D. A.; Luger, S. M.; Phillips, G. L. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14, 1777-1784.
38. Sperr, W.R.; Hauswirth, A. W.; Florian, S.; Öhler, L.; Geissler, K.; Valent, P. Human leukaemic stem cells: a novel target of therapy. Eur. J. Clin. Invest. 2004, 34(S 2), 31-40.
39. Taussig, D.C.; Pearce, D. J.; Simpson, C.; Rohatiner, A. Z.; Lister, T. A.; Kelly, G.; Luongo, J. L.M.; Danet-Desnoyers, G.A.; Bonnet, D. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106, 4086-4092.
40. Hauswirth, A.W.; Florian, S.; Printz, D.; Sotlar, K.; Krauth, M. T.; Fritsch, G.; Schernthaner, G. H.; Wacheck, V.; Selzer, E.; Sperr, W. R.; Valent, P. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur. J. Clin. Invest. 2007, 37, 73-82.
41. Majeti, R.; Chao, M.P.; Alizadeh, A. A.; Pang, W.W.; Jaiswal, S.; Gibbs, K. D.; van Rooijen, N.; Weissman, I. L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138, 286-299.
42. Jin, L.; Hope, K. J.; Zhai, Q.; Smadja-Joffe, F.; Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12, 1167-1174.
43. Jørgensen, H. G.; Holyoake, T. L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans. 2007, 35, 1347-1351.
44. Lemoli, R. M.; Salvestrini, V.; Bianchi, E.; Bertolini, F.; Fogli, M.; Amabile, M.; Tafuri, A.; Salati, S.; Zini, R.; Testoni, N.; Rabascio, C.; Rossi, L.; Martin-Padura, I.; Castagnetti, F.; Marighetti, P.; Martinelli, G.; Baccarani, M.; Ferrari, S.; Manfredini, R. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009, 114, 5191-5200.
45. Chen, Y.; Hu, Y.; Zhang, H.; Peng, C.; Li, S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat. Genet. 2009, 41, 783-792.
46. Guzman, M. L.; Neering, S. J.; Upchurch, D.; Grimes, B.; Howard, D. S.; Rizzieri, D. A.; Luger, S. M.; Jordan, C. T. Nuclear factorkappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98, 2301-2307.
47. Xu, Q.; Simpson, S. E.; Scialla, T. J.; Bagg, A.; Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102, 972-980.
48. Raaphorst, F. M. Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. Trends Immunol. 2003, 24, 522-524.
49. McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Bertrand, F. E.; Ludwig, D. E.; Bäsecke, J., Libra, M.; Stivala, F.; Milella, M.; Tafuri, A.; Lunghi, P.; Bonati, A.; Martelli, A. M. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008, 22, 708-722.
50. Majeti, R.; Becker, M. W.; Tian, Q.; Lee, T. L.; Yan, X.; Liu, R.; Chiang, J. H.; Hood, L.; Clarke, M. F.; Weissman, I. L. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. (USA) 2009, 106, 3396-3401.
51. Yoshimoto, G.; Miyamoto, T.; Jabbarzadeh-Tabrizi, S.; Iino, T.; Rocnik, J. L.; Kikushige, Y.; Mori, Y.; Shima, T.; Iwasaki, H.; Takenaka, K.; Nagafuji, K.; Mizuno, S.; Niiro, H.; Gilliland, G. D.; Akashi, K. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 2009, 114, 5034-5043.
52. Abrahamsson, A. E.; Geron, I.; Gotlib, J.; Dao, K. H.; Barroga, C. F.; Newton, I. G.; Giles, F. J.; Durocher, J.; Creusot, R. S.; Karimi, M.; Jones, C.; Zehnder, J. L.; Keating, A.; Negrin, R. S.; Weissman, I. L.; Jamieson, C. H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. (USA) 2009, 106, 3925-3929.
53. Gal, H.; Amariglio, N.; Trakhtenbrot, L.; Jacob-Hirsh, J.; Margalit, O.; Avigdor, A.; Nagler, A.; Tavor, S.; Ein-Dor, L.; Lapidot, T.; Domany, E.; Rechavi, G.; Givol, D. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20, 2147-2154.
54. Zhou, L. L.; Zhao, Y.; Ringrose, A.; DeGeer, D.; Kennah, E.; Lin, A.E.; Sheng, G.; Li, X. J.; Turhan, A.; Jiang, X. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J. Exp. Med. 2008, 205, 2657-2671.
55. Diaz-Blanco, E.; Bruns, I.; Neumann, F.; Fischer, J. C.; Graef, T.; Rosskopf, M.; Brors, B.; Pechtel, S.; Bork, S.; Koch, A.; Baer, A.; Rohr, U. P.; Kobbe, G.; Haeseler, A.; Gattermann, N.; Haas, R.; Kronenwett, R. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007, 21, 494-504.
56. Tallman, M. S.; Gilliland, D. G.; Rowe, J. M. Drug therapy for acute myeloid leukemia. Blood 2005, 106, 1154-1163.
57. Ravandi, F.; Estrov, Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin. Cancer Res. 2006, 12, 340-244.
58. de Jonge-Peeters, S. D.; Kuipers, F.; de Vries, E.G.; Vellenga, E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit. Rev. Oncol. Hematol. 2007, 62, 214-226.
59. Jiang, X.; Zhao, Y.; Smith, C.; Gasparetto, M.; Turhan, A.; Eaves, A.; Eaves, C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21, 926-935.
60. Jiang, X.; Saw, K. M.; Eaves, A.; Eaves, C. Instability of BCR- ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl. Cancer Inst. 2007, 99, 680-693.
61. Stuart, S. A., Minami, Y., Wang, J. Y. The CML stem cell: evolution of the progenitor. Cell Cycle 2009, 8, 1338-1343.
62. Angstreich, G. R.; Matsui, W.; Huff, C. A.; Vala, M. S.; Barber, J.; Hawkins, A. L.; Griffin, C. A.; Smith, B. D.; Jones, R. J. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br. J. Haematol. 2005, 130, 373-381.
63. Rousselot, P.; Huguet, F.; Rea, D.; Legros, L.; Cayuela, J. M.; Maarek, O.; Blanchet, O.; Marit, G.; Gluckman, E.; Reiffers, J.; Gardembas, M.; Mahon, F. X. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109, 58-60.
64. Melo, J. V.; Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer. 2007, 7, 441-453.
65. Valent, P.; Deininger, M. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leuk. Lymphoma 2008, 49, 604-609.
66. Deininger, M. Resistance and relapse with imatinib in CML: causes and consequences. J. Natl. Compr. Canc. Netw. 2008, 6(S2), S11-S21.
67. Jawad, M.; Seedhouse, C.; Mony, U.; Grundy, M.; Russell, N. H.; Pallis, M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24, 74-80.
68. Pellicano, F.; Cilloni, D.; Helgason, G. V.; Messa, F.; Panuzzo, C.; Arruga, F.; Bracco, E.; Allan, E.; Huntly, B. J.; Holyoake, T. L.; Saglio, G. FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. Blood 2010, 115, 2983.
69. Gleixner, K. V.; Mayerhofer, M.; Vales, A.; Gruze, A.; Hörmann, G.; Cerny-Reiterer, S.; Lackner, E.; Hadzijusufovic, E.; Herrmann, H.; Iyer, A. K.; Krauth, M. T.; Pickl, W. F.; Marian, B.; Panzer-Grümayer, R.; Sillaber, C.; Maeda, H.; Zielinski, C.; Valent, P. Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr. Cancer Drug Targets 2009, 9, 675-689.
70. Mony, U.; Jawad, M.; Seedhouse, C.; Russell, N.; Pallis, M. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia 2008, 22, 1395-1401.
71. Shiozawa, Y.; Havens, A. M.; Pienta, K. J.; Taichman, R. S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22, 941-950.
72. Konopleva, M.; Tabe, Y.; Zeng, Z.; Andreeff, M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 2009, 12, 103-113.
73. Michor, F.; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435, 1267-1270.
74. Roeder, I.; Horn, M.; Glauche, I.; Hochhaus, A.; Müller, M. C.; Löffler, M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 2006, 12, 1181-1184.
75. Stein, A.; Kalebic, T.; Bottino, D. Bcr-Abl kinetics suggest selfrenewing leukemic cells are reduced during imatinib treatment. Blood 2009, 114, 206.
76. Guastafierro, S.; Falcone, U.; Celentano, M.; Coppola, M.; Ferrara, M. G.; Sica, A. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk. Res. 2009, 33, 1079-1081.
77. Quintás-Cardama, A.; Kantarjian, H. M.; Cortes, J. E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16, 122-131.
78. Willis, S. G.; Lange, T.; Demehri, S.; Otto, S.; Crossman, L.; Niederwieser, D.; Stoffregen, E. P.; McWeeney, S.; Kovacs, I.; Park, B.; Druker, B. J.; Deininger, M. W. High-sensitivity detection of BCR- ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106, 2128-2137.
79. Goldman, J. M.; Melo, J. V. BCR-ABL in chronic myelogenous leukemia--how does it work? Acta. Haematol. 2008, 119, 212-217.
80. Lange, T.; Park, B.; Willis, S. G.; Deininger, M. W. BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? Cell Cycle 2005, 4, 1761-1766.
81. Mrózek, K.; Marcucci, G.; Paschka, P.; Whitman, S. P.; Bloomfield, C. D. Clinical relevance of mutations and geneexpression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007, 109, 431-448.
82. Gaidzik, V.; Döhner, K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin. Oncol. 2008, 35, 346-355.
83. Nimer, S. D. Is it important to decipher the heterogeneity of normal karyotype AML? Best. Pract. Res. Clin. Haematol. 2008, 21, 43-52.
84. Andreeff, M.; Konopleva, M. Mechanisms of drug resistance in AML. Cancer Treat. Res. 2002, 112, 237-262.
85. Thomas, X.; Campos, L.; Le, Q. H.; Guyotat, D. Heat shock proteins and acute leukemias. Hematology 2005, 10, 225-235.
86. Roumier, C.; Cheok, M. H. Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics 2009, 10, 1839-1851.
87. Mrózek, K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin. Oncol. 2008, 35, 365-377.
88. Cortes, J. E.; Talpaz, M.; Giles, F.; O'Brien, S.; Rios, M. B.; Shan, J.; Garcia-Manero, G.; Faderl, S.; Thomas, D. A.; Wierda, W.; Ferrajoli, A.; Jeha, S.; Kantarjian, H. M. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101, 3794-3800
89. Haase, D.; Germing, U.; Schanz, J.; Pfeilstöcker, M.; Nösslinger, T.; Hildebrandt, B.; Kundgen, A.; Lübbert, M.; Kunzmann, R.; Giagounidis, A. A.; Aul, C.; Trümper, L.; Krieger, O.; Stauder, R.; Müller, T. H.; Wimazal, F.; Valent, P.; Fonatsch, C.; Steidl, C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110, 4385-4395.
90. Schmidt, C.A.; Przybylski, G. K. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis? Int. Rev. Immunol. 2001, 20, 107-115.
91. Reid, A.G.; De Melo, V.A.; Elderfield, K.; Clark, I.; Marin, D.; Apperley, J.; Naresh, K. N. Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk. Res. 2009, 33, 418-425.
92. Oh, S. H.; Park, T. S.; Kim, H. R.; Lee, J. Y.; Kim, J. H.; Shin, J. H.; Lee, J. N. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leuk. Res. 2009, 33, 195-198.
93. Sperr, W.R.; Horny, H. P.; Valent, P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 2002, 127, 140-142.
94. Tzankov, A.; Sotlar, K.; Muhlematter, D.; Theocharides, A.; Went, P.; Jotterand, M.; Horny, H. P.; Dirnhofer, S. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J. Clin. Pathol. 2008, 61, 958-961.
95. Goradia, A.; Bayerl, M.; Cornfield, D. The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. Int. J. Clin. Exp. Pathol. 2008, 1, 448-456.
96. Gunsilius, E.; Duba, H. C.; Petzer, A. L.; Kähler, C.M.; Grünewald, K.; Stockhammer, G.; Gabl, C.; Dirnhofer, S.; Clausen, J.; Gastl, G. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000, 355, 1688-1691.
97. Streubel, B.; Chott, A.; Huber, D.; Exner, M.; Jäger, U.; Wagner, O.; Schwarzinger, I. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 2004, 351, 250-259.
98. Wu, J.; Huang, L.; Huang, M.; Liu, W.; Zheng, M.; Cao, Y.; Liu, Y.; Zhang, Y.; Lu, Y.; Xu, G.; Wang, S.; Ma, D.; Zhou, J. Dominant contribution of malignant endothelial cells to endotheliopoiesis in chronic myeloid leukemia. Exp. Hematol. 2009, 37, 87-91.
99. Mirshahi, P.; Rafii, A.; Vincent, L.; Berthaut, A.; Varin, R.; Kalantar, G.; Marzac, C.; Calandini, O. A.; Marie, J. P.; Soria, C.; Soria, J.; Mirshahi, M. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009, 23, 1039-1048.
100. Griswold, I. J.; MacPartlin, M.; Bumm, T.; Goss, V. L.; O'Hare, T.; Lee, K. A.; Corbin, A. S.; Stoffregen, E. P.; Smith, C.; Johnson, K.; Moseson, E. M.; Wood, L. J.; Polakiewicz, R. D.; Druker, B. J.; Deininger, M. W. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 2006, 26, 6082-6093.
101. Kralovics, R.; Teo, S. S.; Li, S.; Theocharides, A.; Buser, A. S.; Tichelli, A.; Skoda, R. C. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myelopro-liferative disorders. Blood 2006, 108, 1377-1380.
102. Schaub, F. X.; Jäger, R.; Looser, R.; Hao-Shen, H.; Hermouet, S.; Girodon, F.; Tichelli, A.; Gisslinger, H.; Kralovics, R.; Skoda, R. C. Clonal analysis of deletions on chromosome 20q and JAK2- V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 2009, 113, 2022-2027.
103. Lambert, J. R.; Everington, T.; Linch, D. C.; Gale, R. E. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009, 114, 3018-3023.
104. Sotlar, K.; Fridrich, C.; Mall, A.; Jaussi, R.; Bültmann, B.; Valent, P.; Horny, H. P. Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk. Res. 2002, 26, 979-984.
105. Gotlib, J.; Berubé, C.; Growney, J. D.; Chen, C. C.; George, T. I.; Williams, C.; Kajiguchi, T.; Ruan, J.; Lilleberg, S. L.; Durocher, J. A.; Lichy, J. H.; Wang, Y.; Cohen, P. S.; Arber, D. A.; Heinrich, M. C.; Neckers, L.; Galli, S. J.; Gilliland, D. G.; Coutré, S. E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106, 2865-2870.
106. Sotlar, K.; Bache, A.; Stellmacher, F.; Bültmann, B.; Valent, P.; Horny, H. P. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J. Mol. Diagn. 2008, 10, 58-66.
107. Mecucci, C.; Rege-Cambrin, G.; Michaux, J. L.; Tricot, G.; Van den Berghe, H. Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br. J. Haematol. 1986, 64, 699-706.
108. Hauswirth, A. W.; Sperr, W. R.; Ghannadan, M.; Schernthaner, G. H.; Jordan, J. H.; Fritsche-Polanz, R.; Simonitsch-Klupp, I.; Födinger, M.; Lechner, K.; Valent, P. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk. Res. 2002, 26, 601-606.
109. Escribano, L.; Alvarez-Twose, I.; Sánchez-Muñoz, L.; Garcia-Montero, A.; Núñez, R.; Almeida, J.; Jara-Acevedo, M.; Teodósio, C.; García-Cosío, M.; Bellas, C.; Orfao, A. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J. Allergy Clin. Immunol. 2009, 124, 514-521.
110. Fritsche-Polanz, R.; Jordan, J. H.; Feix, A.; Sperr, W. R.; Sunder-Plassmann, G.; Valent, P.; Födinger, M. Mutation analysis of CKIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 2001, 113, 357-364.
111. Theocharides, A.; Boissinot, M.; Girodon, F.; Garand, R.; Teo, S. S.; Lippert, E.; Talmant, P.; Tichelli, A.; Hermouet, S.; Skoda, R. C. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2- V617F mutation. Blood 2007, 110, 375-379.
112. Hsiao, H. H.; Yang, W. C.; Liu, Y. C.; Lee, C. P.; Lin, S. F. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leuk. Res. 2008, 32, 1323-1234.
113. de Witte, T.; Brand, R.; van Biezen, A.; Mufti, G.; Ruutu, T.; Finke, J.; von dem Borne, P.; Vitek, A.; Delforge, M.; Alessandrino, P.; Harlahakis, N.; Russell, N.; Martino, R.; Verdonck, L.; Kröger, N.; Niederwieser, D. European Blood and Marrow Transplantation Group (EBMT), Chronic Leukemia Working Party (CLWP)-MDS subcommittee. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br. J. Haematol. 2009, 146, 627-636.
114. Hochhaus, A. First-Line management of CML: a state of the art review. J. Natl. Compr. Canc. Netw. 2008, 6(S2), S1-S10.
115. Koreth, J.; Schlenk, R.; Kopecky, K. J.; Honda, S.; Sierra, J.; Djulbegovic, B. J.; Wadleigh, M.; DeAngelo, D. J.; Stone, R. M.; Sakamaki, H.; Appelbaum, F. R.; Döhner, H.; Antin, J. H.; Soiffer, R. J.; Cutler, C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and metaanalysis of prospective clinical trials. J.A.M.A. 2009, 301, 2349-2361.
116. Saussele, S.; Lauseker, M.; Gratwohl, A.; Beelen, D. W.; Bunjes, D.; Schwerdtfeger, R.; Kolb, H. J.; Ho, A. D.; Falge, C.; Holler, E.; Schlimok, G.; Zander, A. R.; Arnold, R.; Kanz, L.; Dengler, R.; Haferlach, C.; Schlegelberger, B.; Pfirrmann, M.; Müller, M. C.; Schnittger, S.; Leitner, A.; Pletsch, N.; Hochhaus, A.; Hasford, J.; Hehlmann, R. Allogeneic hematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinib era; evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010, 115, 1880-1885.
117. Bloomfield, C. D.; Lawrence, D.; Byrd, J. C.; Carroll, A.; Pettenati, M. J.; Tantravahi, R.; Patil, S. R.; Davey, F. R.; Berg, D. T.; Schiffer, C. A.; Arthur, D. C.; Mayer, R. J. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998, 58, 4173-4179.
118. Neubauer, A.; Maharry, K.; Mrózek, K.; Thiede, C.; Marcucci, G.; Paschka, P.; Mayer, R. J.; Larson, R. A.; Liu, E. T.; Bloomfield, C. D. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2008, 26, 4603-4909.
119. Schlenk, R.F.; Döhner, K.; Krauter, J.; Fröhling, S.; Corbacioglu, A.; Bullinger, L.; Habdank, M.; Späth, D.; Morgan, M.; Benner, A.; Schlegelberger, B.; Heil, G.; Ganser, A.; Döhner, H. German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 2008, 358, 1909-1918.
120. Dombret, H.; Preudhomme, C.; Boissel, N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr. Opin. Hematol. 2009, 16, 92-97.
121. Martinelli, G.; Soverini, S.; Rosti, G.; Cilloni, D.; Baccarani, M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005, 90, 534-541.
122. Järås, M.; Johnels, P.; Hansen, N.; Agerstam, H.; Tsapogas, P.; Rissler, M.; Lassen, C.; Olofsson, T.; Bjerrum, O.W.; Richter, J.; Fioretos, T. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. (USA) 2010, 107, 16280-16285.
123. Abutalib, S. A.; Tallman, M. S. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr. Pharm. Biotechnol. 2006, 7, 343-369.
124. Kimura, S.; Ashihara, E.; Maekawa, T. New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Curr. Pharm. Biotechnol. 2006, 7, 371-379.
125. Weisberg, E.; Barrett, R.; Liu, Q.; Stone, R.; Gray, N.; Griffin, J. D. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist. Updat. 2009, 12, 81-89.
126. Weisberg, E.; Manley, P. W.; Cowan-Jacob, S. W.; Hochhaus, A.; Griffin, J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 2007, 7, 345-356.
127. Krause, D. S.; Van Etten, R. A. Right on target: eradicating leukemic stem cells. Trends Mol. Med. 2007, 13, 470-481.
128. Martinelli, G.; Iacobucci, I.; Papayannidis, C.; Soverini, S. New targets for Ph+ leukaemia therapy. Best. Pract. Res. Clin. Haematol. 2009, 22, 445-454.
129. Jin, L.; Lee, E. M.; Ramshaw, H. S.; Busfield, S. J.; Peoppl, A. G.; Wilkinson, L.; Guthridge, M. A.; Thomas, D.; Barry, E. F.; Boyd, A.; Gearing, D. P.; Vairo, G.; Lopez, A. F.; Dick, J. E.; Lock, R. B. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell. Stem Cell 2009, 5, 31-42.
130. Krause, A.; Luciana, M.; Krause, F.; Rego, E. M. Targeting the acute myeloid leukemia stem cells. Anticancer Agents Med. Chem. 2010, 10, 104-110.
131. Sievers, E. L.; Appelbaum, F. R.; Spielberger, R. T.; Forman, S. J.; Flowers, D.; Smith, F. O.; Shannon-Dorcy, K.; Berger, M. S.; Bernstein, I. D. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999, 93, 3678-3684.
132. Larson, R. A.; Sievers, E. L.; Stadtmauer, E. A.; Löwenberg, B.; Estey, E. H.; Dombret, H.; Theobald, M.; Voliotis, D.; Bennett, J. M.; Richie, M.; Leopold, L. H.; Berger, M. S.; Sherman, M. L.; Loken, M. R.; van Dongen, J. J.; Bernstein, I. D.; Appelbaum, F. R. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104, 1442-1452.
133. Pagel, J. M.; Appelbaum, F. R.; Eary, J. F.; Rajendran, J.; Fisher, D. R.; Gooley, T.; Ruffner, K.; Nemecek, E.; Sickle, E.; Durack, L.; Carreras, J.; Horowitz, M. M.; Press, O. W.; Gopal, A. K.; Martin, P. J.; Bernstein, I. D.; Matthews, D. C. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107, 2184-2191.
134. Frankel, A.; Liu, J. S.; Rizzieri, D.; Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients Targeting Neoplastic Stem Cells with acute myeloid leukemia and myelodysplasia. Leuk. Lymphoma 2008, 49, 543-553.
135. Zhao, C.; Blum, J.; Chen, A.; Kwon, H. Y.; Jung, S. H.; Cook, J. M.; Lagoo, A.; Reya, T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12, 528-541.
136. Martelli, A. M.; Tazzari, P. L.; Evangelisti, C.; Chiarini, F.; Blalock, W. L.; Billi, A. M.; Manzoli, L.; McCubrey, J. A.; Cocco, L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr. Med. Chem. 2007, 14, 2009-2023.
137. Samanta, A. K.; Chakraborty, S. N.; Wang, Y.; Kantarjian, H.; Sun, X.; Hood, J.; Perrotti, D.; Arlinghaus, R. B. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28, 1669-1681.
138. Tefferi, A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J. Cell. Mol. Med. 2009, 13, 215-237.
139. Jagani, Z.; Dorsch, M.; Warmuth, M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010, 9, 3449-3456.
140. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107, 4532-4539.
141. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; Richon, V.; Bhalla, K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS- 354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin. Cancer Res. 2006, 12, 5869-5878.
142. Copland, M.; Pellicano, F.; Richmond, L.; Allan, E. K.; Hamilton, A.; Lee, F. Y.; Weinmann, R.; Holyoake, T. L. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111, 2843-2853.
143. Hu, Z.; Pan, X.F.; Wu, F.Q.; Ma, L.Y.; Liu, D.P.; Liu, Y.; Feng, T.T.; Meng, F.Y.; Liu, X.L.; Jiang, Q.L.; Chen, X.Q.; Liu, J.L.; Liu, P.; Chen, Z.; Chen, S.J.; Zhou, G.B. Synergy between protea-some inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS. One 2009, 4, e6257.
144. Irvine, D. A.; Heaney, N. B.; Holyoake, T. L. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Rev. 2010, 24, 1-9.
145. Becker, P. S. Growth factor priming in therapy of acute myelogenous leukemia. Curr. Hematol. Rep. 2004, 3, 413-418.
146. Drummond, M. W.; Heaney, N.; Kaeda, J.; Nicolini, F. E.; Clark, R. E.; Wilson, G.; Shepherd, P.; Tighe, J.; McLintock, L.M.; Hughes, T.; Holyoake, T. L. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 2009, 23, 1199-1201.
147. Mahon, F. X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J. M.; Melo, J. V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101, 2368-2373.
148. Brendel, C.; Scharenberg, C.; Dohse, M.; Robey, R. W.; Bates, S. E.; Shukla, S.; Ambudkar, S. V.; Wang, Y.; Wennemuth, G.; Burchert, A.; Boudriot, U.; Neubauer, A. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21, 1267-1275.
149. Mahon, F.X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P. W.; Leroy, C.; Etienne, G.; Roche, S.; Pasquet, J. M. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68, 9809-9816.
150. Weisberg, E.; Catley, L.; Wright, R. D.; Moreno, D.; Banerji, L.; Ray, A.; Manley, P. W.; Mestan, J.; Fabbro, D.; Jiang, J.; Hall-Meyers, E.; Callahan, L.; DellaGatta, J. L.; Kung, A. L.; Griffin, J. D. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007, 109, 2112-2120.
151. O'Hare, T.; Walters, D. K.; Stoffregen, E. P.; Sherbenou, D. W.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 2005, 11, 6987-6993.
152. Komarova, N. L.; Katouli, A. A.; Wodarz, D. Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PloS. One 2009, 4, e4423.
153. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 994-996.
154. Rix, U.; Hantschel, O.; Dürnberger, G.; Remsing-Rix L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Köcher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110, 4055-4063.
155. Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5, 616-624.
156. Mayerhofer, M.; Gleixner, K. V.; Mayerhofer, J.; Hoermann, G.; Jaeger, E.; Aichberger, K. J.; Ott, R. G.; Greish, K.; Nakamura, H.; Derdak, S.; Samorapoompichit, P.; Pickl, W. F.; Sexl, V.; Esterbauer, H.; Schwarzinger, I.; Sillaber, C.; Maeda, H.; Valent, P. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 2008, 111, 2200-2210.
157. Spaeth, E. L.; Dembinski J. L.; Sasser, A. K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4, e4992.
158. Uy, G. L.; Rettig, M. P.; McFarland, K.; Hladnik, L.; Kulkarni, S.; Abboud, C. N.; Cashen, A.F.; Stockerl-Goldstein, K.; Vij, R.; Westervelt, P.; DiPersio, J.F. A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML. Blood 2009, 114, 325.
159. Petit, I.; Karajannis, M. A.; Vincent, L.; Young, L.; Butler, J.; Hooper, A. T.; Shido, K.; Steller, H.; Chaplin, D. J.; Feldman, E.; Rafii, S. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 2008, 111, 1951-1961.